Cargando…

Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model

BACKGROUND: A recent recalibration of the ONCOTYROL Prostate Cancer Outcome and Policy (PCOP) Model, assuming that latent prostate cancer (PCa) detectable at autopsy might be detectable by screening as well, resulted in considerable worsening of the benefit-harm balance of screening. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mühlberger, Nikolai, Boskovic, Kristijan, Krahn, Murray D., Bremner, Karen E., Oberaigner, Willi, Klocker, Helmut, Horninger, Wolfgang, Sroczynski, Gaby, Siebert, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485506/ https://www.ncbi.nlm.nih.gov/pubmed/28651567 http://dx.doi.org/10.1186/s12889-017-4439-9

Ejemplares similares

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008
por: Oberaigner, Willi, et al.
Publicado: (2011)

Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria
por: Jahn, Beate, et al.
Publicado: (2019)

Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program
por: Heidegger, Isabel, et al.
Publicado: (2015)

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality
por: Mühlberger, Nikolai, et al.
Publicado: (2009)

The economic impact of prevention, monitoring and treatment strategies for iodine deficiency disorders in Germany
por: Schaffner, Monika, et al.
Publicado: (2020)

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer()
por: Heidegger, Isabel, et al.
Publicado: (2013)

High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance
por: Heidegger, Isabel, et al.
Publicado: (2015)

Antidiabetic drugs influence molecular mechanisms in prostate cancer
por: Pircher, Andreas, et al.
Publicado: (2018)

Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment
por: Siebert, Uwe, et al.
Publicado: (2003)

Mitochondrial Haplogroups and Control Region Polymorphisms Are Not Associated with Prostate Cancer in Middle European Caucasians
por: Mueller, Edith E., et al.
Publicado: (2009)

Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature
por: Pircher, Andreas, et al.
Publicado: (2019)

Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical
por: Mittendorf, Thomas, et al.
Publicado: (2007)

Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations
por: Hallsson, Lára R., et al.
Publicado: (2023)

Pharmacogenomics Bias - Systematic distortion of study results by genetic heterogeneity
por: Siebert, Uwe, et al.
Publicado: (2008)

Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer
por: Heijnsdijk, Eveline A M, et al.
Publicado: (2020)

Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany
por: Sroczynski, Gaby, et al.
Publicado: (2010)

Stool DNA testing for early detection of colorectal cancer: systematic review using the HTA Core Model(®) for Rapid Relative Effectiveness Assessment
por: Stürzlinger, Heidi, et al.
Publicado: (2023)

Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer
por: Schaefer, G, et al.
Publicado: (2013)

Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer
por: Klocker, Helmut, et al.
Publicado: (2020)

An iterative algorithm for optimizing COVID-19 vaccination strategies considering unknown supply
por: Bicher, Martin, et al.
Publicado: (2022)

Breast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening
por: Oberaigner, Willi, et al.
Publicado: (2010)

Benefit and harm of lymphadenectomy in intermediate risk prostate cancer: comparison of five nomograms
por: Lodeta, Branimir, et al.
Publicado: (2023)

Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P)
por: Waldmann, Annika, et al.
Publicado: (2009)

ASCO 2018: highlights of urothelial cancer and prostate cancer
por: Pichler, Renate, et al.
Publicado: (2018)

Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer
por: Ladurner, Michael, et al.
Publicado: (2021)

Health state utilities among contemporary prostate cancer patients on active surveillance
por: Loeb, Stacy, et al.
Publicado: (2018)

Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online
por: Jahn, Beate, et al.
Publicado: (2017)

Evaluating the effects of a risk-adapted screening program for familial colorectal cancer in individuals between 25 and 50 years of age: study protocol for the prospective population-based intervention study FARKOR
por: Hoffmann, Sabine, et al.
Publicado: (2020)

Cost-Effectiveness of Early Detection and Prevention Strategies for Endometrial Cancer—A Systematic Review
por: Sroczynski, Gaby, et al.
Publicado: (2020)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
por: Roobol, Monique J., et al.
Publicado: (2011)

A population‐based cohort of adult patients with diabetes mellitus in a Western District of Austria: The Diabetes Landeck cohort
por: Haslwanter, Veronika, et al.
Publicado: (2022)

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study
por: Carlsson, Sigrid, et al.
Publicado: (2014)

Treatment of local–regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
por: Wever, E M, et al.
Publicado: (2013)

Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study
por: Callender, Tom, et al.
Publicado: (2019)

Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients
por: Schlick, Bettina, et al.
Publicado: (2016)

The Impact of Cand1 in Prostate Cancer
por: Eigentler, Andrea, et al.
Publicado: (2020)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Serum levels of miR-320 family members are associated with clinical parameters and diagnosis in prostate cancer patients
por: Lieb, Verena, et al.
Publicado: (2017)

KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
por: Schäfer, Georg, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sep9f7k1q7rdi7n0qtj6c6slrk